<DOC>
	<DOC>NCT01125605</DOC>
	<brief_summary>The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.</brief_summary>
	<brief_title>PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases</brief_title>
	<detailed_description>The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness. Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management, dose regimen, and to the effectiveness and safety in special patient groups (children 1-12 years of age), in relation to treatment conformity to the Summary of Product Characteristics (SmPC).</detailed_description>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group". Observational Criteria (=inclusion criteria for documentation): Males and females Children 112 years old Adults &gt;12 years old suffering from nervous diseases, e.g. sleep disorders due to nervousness. Exclusion criteria for documentation: children younger than 1 year no nervous diseases, e.g. sleep disorders due to nervousness. no treatment with PASCONAL NERVENTROPFEN</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>PASCONAL</keyword>
	<keyword>nervousness</keyword>
	<keyword>nervosity</keyword>
	<keyword>sleep disorder</keyword>
</DOC>